Back to Research Home
NUSNu Skin Enterprises Inc
Health Care · Other Pharmaceuticals · Micro
$4.79−2.64%
As of 23 Oct 2026Mkt cap $235M
Stage 13
AVOID
Fundamentals
26.9/75
Technical
5.2/15
Independent
32.1/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +3.7%
- 3M
- −6.8%
- 6M
- −36.5%
- 1Y
- −55.9%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —Hist median 4.2x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 22.3x
- FCF yield
- 4.5%
Quality
- ROIC
- 6.5%
- Operating margin
- 2.5%
- FCF margin
- 3.1%
- Current ratio
- 2.1x
Growth
- Revenue growth
- −14.3%Latest FY YoY
- Revenue CAGR
- −13.8%
- EPS CAGR
- +2.7%
- FCF CAGR
- −10.9%
Capital
- Share-count trend
- +0.4%3Y annualised
- Net cash
- $14M-0.2x OCF
Annual trend
- CAGR 2021–2025
- −13.8%
- Latest · 2025
- $1B
- YoY
- −14.3%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded